Profile

David House

Chief Financial Officer, Armata Pharmaceuticals, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

David House has been Chief Financial Officer of Armata Pharmaceuticals, Inc. since July 17, 2026, according to the company's filing of July 20, 2026.¹

The filing gives David House's previous role as Senior Vice President, Finance and principal financial officer at Armata Pharmaceuticals, Inc.¹ David House already worked at Armata Pharmaceuticals, Inc. when appointed, so the record counts the move as an internal promotion.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Armata Pharmaceuticals, Inc. (ARMP) Biological Products, (No Diagnostic Substances)	Chief Financial Officer	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

July 17, 2026effective
Armata Pharmaceuticals, Inc. appointed David House as Chief Financial Officer, effective July 17, 2026.
On July 17, 2026, the Board of Directors (the “ Board ”) of Armata Pharmaceuticals, Inc. (the “ Company ”) promoted and appointed David House as the Company’s Chief Financial Officer, effective July 17, 2026.
[1] Filing by Armata Pharmaceuticals, Inc., filed with the SEC on July 20, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Armata Pharmaceuticals, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 20, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or David House wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.